Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis


The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid accumulates in the brain during development, and has been implicated in learning and memory development. DEA, a metabolite derived from DHA, also has been shown to accelerate neuronal growth and development. In vitro studies in which neural progenitor cells were treated with DEA derivatives showed an increase in the number of somatic neurons produced after differentiation.



Potential Commercial Applications: Competitive Advantages:
  • Neurogenesis
  • Neurite growth
  • Synaptogenesis
  • Therapeutics for traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
 
  • These derivatives of DEA provide increased potency and hydrolysis resistance compared to DEA.


Development Stage:
  • Early-stage
  • In vitro data available
  • Prototype


Inventors:

Erika Englund (NCATS)  ➽ more inventions...

Juan Marugan (NCATS)  ➽ more inventions...

Samarjit Patnaik (NCATS)  ➽ more inventions...

Hee-Yong Kim (NIAAA)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,422,308 issued 2016-08-23
PCT Application No. PCT/US2013/032333
US Application No. 14/387,410
Patents issued in Germany, France, United Kingdom

Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-070-2012/0
Updated: Nov 1, 2017